Omeros Debt to Equity Ratio 2010-2025 | OMER
Current and historical debt to equity ratio values for Omeros (OMER) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Omeros debt/equity for the three months ending March 31, 2025 was 0.00.
| Omeros Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-03-31 | $0.45B | $-0.21B | -2.10 |
| 2024-12-31 | $0.46B | $-0.18B | -2.52 |
| 2024-09-30 | $0.47B | $-0.15B | -3.03 |
| 2024-06-30 | $0.48B | $-0.13B | -3.86 |
| 2024-03-31 | $0.51B | $-0.07B | -7.13 |
| 2023-12-31 | $0.40B | $-0.03B | -16.14 |
| 2023-09-30 | $0.51B | $-0.01B | -36.34 |
| 2023-06-30 | $0.51B | $0.02B | 24.72 |
| 2023-03-31 | $0.51B | $0.06B | 9.20 |
| 2022-12-31 | $0.51B | $0.09B | 5.90 |
| 2022-09-30 | $0.50B | $-0.05B | -10.88 |
| 2022-06-30 | $0.38B | $-0.03B | -11.57 |
| 2022-03-31 | $0.37B | $-0.01B | -75.98 |
| 2021-12-31 | $0.40B | $0.02B | 16.63 |
| 2021-09-30 | $0.39B | $-0.26B | -1.47 |
| 2021-06-30 | $0.39B | $-0.25B | -1.59 |
| 2021-03-31 | $0.38B | $-0.22B | -1.73 |
| 2020-12-31 | $0.30B | $-0.12B | -2.50 |
| 2020-09-30 | $0.31B | $-0.09B | -3.60 |
| 2020-06-30 | $0.23B | $-0.16B | -1.44 |
| 2020-03-31 | $0.25B | $-0.13B | -1.90 |
| 2019-12-31 | $0.25B | $-0.11B | -2.26 |
| 2019-09-30 | $0.23B | $-0.14B | -1.65 |
| 2019-06-30 | $0.22B | $-0.13B | -1.69 |
| 2019-03-31 | $0.22B | $-0.12B | -1.84 |
| 2018-12-31 | $0.20B | $-0.10B | -1.96 |
| 2018-09-30 | $0.17B | $-0.09B | -1.85 |
| 2018-06-30 | $0.16B | $-0.06B | -2.89 |
| 2018-03-31 | $0.12B | $-0.03B | -4.05 |
| 2017-12-31 | $0.12B | $0.00B | -42.34 |
| 2017-09-30 | $0.12B | $0.01B | 12.63 |
| 2017-06-30 | $0.12B | $-0.06B | -2.10 |
| 2017-03-31 | $0.11B | $-0.05B | -2.21 |
| 2016-12-31 | $0.11B | $-0.04B | -2.80 |
| 2016-09-30 | $0.10B | $-0.02B | -4.20 |
| 2016-06-30 | $0.10B | $-0.05B | -1.94 |
| 2016-03-31 | $0.08B | $-0.04B | -1.88 |
| 2015-12-31 | $0.08B | $-0.03B | -2.87 |
| 2015-09-30 | $0.05B | $-0.01B | -5.60 |
| 2015-06-30 | $0.05B | $0.01B | 6.39 |
| 2015-03-31 | $0.05B | $0.02B | 2.43 |
| 2014-12-31 | $0.05B | $-0.04B | -1.25 |
| 2014-09-30 | $0.05B | $-0.03B | -1.95 |
| 2014-06-30 | $0.05B | $-0.01B | -4.86 |
| 2014-03-31 | $0.05B | $0.01B | 9.76 |
| 2013-12-31 | $0.04B | $-0.02B | -1.90 |
| 2013-09-30 | $0.04B | $-0.02B | -1.50 |
| 2013-06-30 | $0.04B | $-0.01B | -2.88 |
| 2013-03-31 | $0.03B | $-0.02B | -2.12 |
| 2012-12-31 | $0.03B | $-0.01B | -5.07 |
| 2012-09-30 | $0.03B | $0.00B | -40.95 |
| 2012-06-30 | $0.03B | $-0.02B | -1.49 |
| 2012-03-31 | $0.03B | $-0.01B | -2.66 |
| 2011-12-31 | $0.03B | $-0.01B | -5.86 |
| 2011-09-30 | $0.03B | $0.00B | 7.58 |
| 2011-06-30 | $0.03B | $0.01B | 3.09 |
| 2011-03-31 | $0.03B | $0.02B | 2.26 |
| 2010-12-31 | $0.03B | $0.02B | 1.23 |
| 2010-09-30 | $0.01B | $0.02B | 0.62 |
| 2010-06-30 | $0.02B | $0.03B | 0.50 |
| 2010-03-31 | $0.02B | $0.04B | 0.45 |
| 2009-12-31 | $0.02B | $0.04B | 0.44 |
| 2009-09-30 | $0.02B | $-0.01B | -1.48 |
| 2009-06-30 | $0.00B | $0.00B | 0.00 |
| 2009-03-31 | $0.00B | $0.00B | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.195B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $232.564B | 27.96 |
| Boston Scientific (BSX) | United States | $154.721B | 38.73 |
| Stryker (SYK) | United States | $149.011B | 31.16 |
| EssilorLuxottica (ESLOY) | France | $125.383B | 0.00 |
| Medtronic (MDT) | Ireland | $110.530B | 15.67 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.919B | 0.00 |
| Haleon (HLN) | United Kingdom | $46.856B | 26.72 |
| ResMed (RMD) | United States | $37.567B | 28.22 |
| GE HealthCare Technologies (GEHC) | United States | $34.277B | 16.27 |
| Agilent Technologies (A) | United States | $33.923B | 22.11 |
| Terumo (TRUMY) | Japan | $27.568B | 35.81 |
| Koninklijke Philips (PHG) | Netherlands | $23.187B | 16.27 |
| Insulet (PODD) | United States | $21.804B | 85.59 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.151B | 11.66 |
| Baxter (BAX) | United States | $15.652B | 11.69 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.231B | 0.00 |
| Demant (WILYY) | Denmark | $9.110B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.625B | 23.06 |
| Lantheus Holdings (LNTH) | United States | $5.586B | 14.09 |
| Prestige Consumer Healthcare (PBH) | United States | $4.010B | 17.91 |
| Perrigo (PRGO) | Ireland | $3.653B | 9.26 |
| Haemonetics (HAE) | United States | $3.592B | 16.36 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.330B | 27.68 |
| ICU Medical (ICUI) | United States | $3.216B | 23.72 |
| GN Store Nord (GNNDY) | Denmark | $2.307B | 19.11 |
| QuidelOrtho (QDEL) | United States | $1.941B | 13.35 |
| LeMaitre Vascular (LMAT) | United States | $1.862B | 41.62 |
| AtriCure (ATRC) | United States | $1.628B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.271B | 12.90 |
| Acuren (TIC) | United States | $1.252B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.120B | 25.19 |
| Neogen (NEOG) | United States | $1.040B | 13.31 |
| BioLife Solutions (BLFS) | United States | $1.020B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.018B | 13.02 |
| Kestra Medical Technologies (KMTS) | United States | $0.919B | 0.00 |
| InMode (INMD) | Israel | $0.889B | 8.96 |
| CeriBell (CBLL) | United States | $0.697B | 0.00 |
| Owens & Minor (OMI) | United States | $0.644B | 5.34 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.606B | 0.00 |
| Evolus (EOLS) | United States | $0.600B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.551B | 0.00 |
| Valneva SE (VALN) | France | $0.489B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.465B | 0.00 |
| Surmodics (SRDX) | United States | $0.416B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.415B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.352B | 12.94 |
| SNDL (SNDL) | Canada | $0.328B | 0.00 |
| Quanterix (QTRX) | United States | $0.328B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.301B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.283B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.273B | 23.03 |
| Cerus (CERS) | United States | $0.260B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.252B | 0.00 |
| ZimVie (ZIMV) | United States | $0.251B | 11.39 |
| Cresco Labs (CRLBF) | United States | $0.250B | 0.00 |
| Brainsway (BWAY) | Israel | $0.248B | 65.50 |
| Aurora Cannabis (ACB) | Canada | $0.239B | 71.00 |
| Biote (BTMD) | United States | $0.234B | 6.58 |
| Canopy Growth (CGC) | Canada | $0.228B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.226B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.192B | 0.00 |
| Organigram Global (OGI) | Canada | $0.188B | 0.00 |
| High Tide (HITI) | Canada | $0.187B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.183B | 14.93 |
| Verano Holdings (VRNOF) | United States | $0.175B | 0.00 |
| Exagen (XGN) | United States | $0.149B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.136B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.120B | 14.79 |
| Jin Medical (ZJYL) | China | $0.102B | 0.00 |
| Veru (VERU) | United States | $0.096B | 0.00 |
| Fonar (FONR) | United States | $0.089B | 11.54 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.089B | 0.00 |
| Apyx Medical (APYX) | United States | $0.085B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.083B | 0.00 |
| MacroGenics (MGNX) | United States | $0.080B | 0.00 |
| Zynex (ZYXI) | United States | $0.079B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.079B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.074B | 0.00 |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Agape ATP (ATPC) | $0.065B | 0.00 | |
| ImmuCell (ICCC) | United States | $0.061B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.059B | 0.00 |
| Nephros (NEPH) | United States | $0.045B | 60.57 |
| United-Guardian (UG) | United States | $0.038B | 13.18 |
| Modular Medical (MODD) | United States | $0.035B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.028B | 0.00 |
| Safety Shot (SHOT) | United States | $0.023B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.019B | 0.00 |
| INLIF (INLF) | $0.016B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| Senestech (SNES) | United States | $0.010B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |